Status:
COMPLETED
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Liver Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Liposomal bupivacaine is a novel long-acting local anesthetic approved by the FDA for postoperative analgesia because of its ability to significantly prolong the analgesic effect for up to 72 hours. U...
Detailed Description
After approved by the Ethics Committee of Zhejiang Cancer Hospital (approval number IRB-2023-941 (IIT)). The study was registered before patient enrollment in Clinicaltrials. Written informed consent ...
Eligibility Criteria
Inclusion
- 18-75 years old;
- American Society of Anesthesiologist physical status I-III;
- Child-Pugh score A-B;
- Non anergic to medication used in this study;
- Optional/scheduled for liver resection;
- Approved participation before study.
Exclusion
- Patients with contraindications for local nerve block such as spinal anatomic structure abnormality or local infection of puncture area;
- Anergic to medications used in this study;
- Patient have chronic pain;
- Patient receiving anticoagulants, opioids or have a history of narcotic abuse or alcohol abuse;
- Unable to complete postoperative pain score assessment or questionnaires or have mental disorders;
- Pregnant;
- BMI ≥30 kg/m2;
- Patient involving in other studies.
Key Trial Info
Start Date :
December 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2024
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06173466
Start Date
December 15 2023
End Date
May 30 2024
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022